Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Thoracic Surgery Clinics|April 27, 2016
Advances in Uniportal Video-Assisted Thoracoscopic Surgery: Pushing the EnvelopeDiego Gonzalez-Rivas, Yang Yang, Calvin Ng
Risk Analysis : an Official Publication of the Society for Risk Analysis|July 6, 2025
Coupling wastewater-based epidemiology with data-driven machine learning for managing public health risksSheree Pagsuyoin, Calvin Ng, Nerissa Molejon, et al.
Thoracic Surgery Clinics|April 12, 2023
Stereotactic Body Radiation Therapy Versus Ablation Versus Surgery for Early-Stage Lung Cancer in High-Risk PatientsConor M Maxwell, Calvin Ng, Hiran C Fernando
Science Advances|August 28, 2024
PneumaOCT: Pneumatic optical coherence tomography endoscopy for targeted distortion-free imaging in tortuous and narrow internal lumensTinghua Zhang, Sishen Yuan, Chao Xu, et al.
Journal of Molecular Liquids|August 11, 2025
Designing functional viologen salts with colossal ionic conductivities through counterion composition and chain length: where is the limit?Seonghyeok L Cox, Si L Chen, Jakob Smith, et al.
International Journal of Cancer|July 30, 2013
Tumor vascularization is critical for oncolytic vaccinia virus treatment of peritoneal carcinomatosisKathryn Ottolino-Perry, Nan Tang, Renee Head, et al.
Lung Cancer (Amsterdam, Netherlands)|June 15, 2023
Stereotactic body radiation therapy and thermal ablation for treatment of NSCLC: A systematic literature review and meta-analysisPaul Laeseke, Calvin Ng, Nicole Ferko, et al.
Journal of Virology|November 13, 2009
Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer modelsKilian Guse, Marta Sloniecka, Iulia Diaconu, et al.
BMC Pulmonary Medicine|April 24, 2025
Stereotactic body radiation therapy and thermal ablation for treatment of patients with pulmonary metastases: a systematic literature review and meta-analysisPaul Laeseke, Calvin Ng, Nicole Ferko, et al.
JTO Clinical and Research Reports|August 14, 2025
CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB-IIIA NSCLCJay M Lee, Jean-Louis Pujol, Jun Zhang, et al.
Pageof 1